Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma

Somaya A. Abdel-Rahman,Moustafa Gabr

DOI: https://doi.org/10.3390/cancers16020435

2024-01-20

Cancers

Abstract:Glioblastoma (GBM), the most aggressive astrocytic glioma, remains a therapeutic challenge despite multimodal approaches. Immunotherapy holds promise, but its efficacy is hindered by the highly immunosuppressive GBM microenvironment. This review underscores the urgent need to comprehend the intricate interactions between glioma and immune cells, shaping the immunosuppressive tumor microenvironment (TME) in GBM. Immunotherapeutic advancements have shown limited success, prompting exploration of immunomodulatory approaches targeting tumor-associated macrophages (TAMs) and microglia, constituting a substantial portion of the GBM TME. Converting protumor M2-like TAMs to antitumor M1-like phenotypes emerges as a potential therapeutic strategy for GBM. The blood–brain barrier (BBB) poses an additional challenge to successful immunotherapy, restricting drug delivery to GBM TME. Research efforts to enhance BBB permeability have mainly focused on small molecules, which can traverse the BBB more effectively than biologics. Despite over 200 clinical trials for GBM, studies on small molecule immunomodulators within the GBM TME are scarce. Developing small molecules with optimal brain penetration and selectivity against immunomodulatory pathways presents a promising avenue for combination therapies in GBM. This comprehensive review discusses various immunomodulatory pathways in GBM progression with a focus on immune checkpoints and TAM-related targets. The exploration of such molecules, with the capacity to selectively target key immunomodulatory pathways and penetrate the BBB, holds the key to unlocking new combination therapy approaches for GBM.

oncology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the challenges in the treatment of glioblastoma (GBM). Although current treatment methods such as surgery, radiotherapy and chemotherapy have made certain progress, the prognosis of GBM is still poor and the quality of life of patients is seriously affected. Especially for recurrent GBM, there is a lack of clear treatment standards, and the existing immunotherapy has limited effectiveness due to the highly immunosuppressive microenvironment of GBM.

Specifically, the paper focuses on the following aspects:

1. **Understanding the complex interactions between GBM and immune cells**: The tumor microenvironment (TME) of GBM has highly immunosuppressive properties, which hinder the effectiveness of immunotherapy. Therefore, in - depth research on the interactions between GBM and immune cells is required to find new treatment targets.

2. **Developing immunomodulatory strategies for tumor - associated macrophages (TAMs) and microglia**: TAMs and microglia account for a large proportion in the TME of GBM and mainly exhibit a pro - tumor M2 - like phenotype. Repolarizing these cells into an anti - tumor M1 - like phenotype may become an effective strategy for treating GBM.

3. **Overcoming the limitations of the blood - brain barrier (BBB) on drug delivery**: The existence of the BBB makes it difficult for most drugs to enter the brain, limiting the application of immunotherapy in GBM. Therefore, the development of small - molecule drugs that can effectively penetrate the BBB is the focus of current research.

4. **Exploring new immune checkpoint inhibitors**: The paper discusses in detail the roles of multiple immune checkpoints (such as PD - 1/PD - L1, TIM - 3, LAG - 3, CTLA - 4, TIGIT and VISTA) in GBM and explores the development potential of small - molecule inhibitors targeting these checkpoints.

In summary, this paper aims to find new treatment strategies by studying the application of small - molecule immunomodulators in the treatment of GBM, so as to improve the prognosis and quality of life of GBM patients.